Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Perceptive Advisors
Biotech
Endeavor nabs $101M for IPF, cancer trials—and asset shopping
Endeavor will use $101M in attempt to beat two idiopathic pulmonary fibrosis drugs from Roche and Boehringer that have been on the market since 2014.
Kyle LaHucik
Feb 7, 2022 8:00am
Mystery revealed: Mythic lands $103M to take on ADC class
Dec 16, 2021 10:30am
Amicus spins off gene therapy unit in $600M SPAC deal
Sep 29, 2021 8:35am
Takeda norovirus vaccine spinout HilleVax snags $135M crossover
Sep 8, 2021 10:25am
Portable test maker Cue Health nets $235M for a post-COVID world
May 13, 2021 1:20pm
Perceptive unveils $515M fund, its 2nd for early-stage biotechs
May 12, 2021 6:55am
